ArticleIntestinal Failure (New York, N.Y.)
Real-life experience of teduglutide use in pediatric patients with short bowel syndrome in Argentina. A multicenter study.
Article in Intestinal Failure (New York, N.Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Optimizing teduglutide treatment regimens in children with short bowel syndrome.Frontiers in pediatrics · 2026Review
- Real-world effectiveness and safety of teduglutide in adult and pediatric patients with short bowel syndrome in Argentina.World journal of gastrointestinal pharmacology and therapeutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Current treatment of patients with chronic intestinal failure due to short bowel syndrome (CIF-SBS) attempts to promote the intestinal adaptation process. Teduglutide (TED) is the first successful pharmacological intervention which enhances natural intestinal adaptation. Aim: To present the long-term results and follow up of all the children treated with TED at specialized intestinal failure units in Argentina. Methods: Multicenter, descriptive, retrospective study of patients aged 1-18 years with CIF-SBS, that initiated TED in specialized centers in Argentina. Sex, age, SBS etiology/anatomy, remaining small bowel length (RBL), 20 % decrease in initial parenteral nutrition (PN) volume, and weaning at 3-6-12 months of treatment are described. Results: Thirty-three patients (11 female) treated with TED between 1/2017 and 8/2023 in 9 centers were included. Median time of CIF-SBS prior to TED was 6.06 (IQR 3.8-10.4) years. Median age at starting TED was 7.5 (IQR 4.8-12.4), range 2.5-18 years. Anatomy types: type 1 in 1; type 2 in 22, and type 3 in 9. Median time of treatment was 1.5 (IQR 0.52-3.2) years.A 20 % reduction of the initial weekly PN volume was obtained in 23 patients (70 %) and complete PN discontinuation without detriment of the nutritional status was achieved in 36 % during the entire follow-up period.The most frequent adverse event was mild abdominal pain, and two patients discontinued the medication due to adverse events. Conclusions: The Argentine experience with TED as part of the intestinal rehabilitation strategies showed good results and adverse events like those reported in other international series.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.